Overview
Medicare Part D is the outpatient prescription-drug benefit within Medicare, established by the Medicare Modernization Act of 2003 and operational since 2006. Unlike Parts A and B which operate through direct Medicare fee-for-service payment, Part D is delivered exclusively through private plans (Prescription Drug Plans or PDPs and Medicare Advantage Prescription Drug plans or MA-PDs) that contract with CMS. Beneficiaries enroll voluntarily; premium structure and plan design vary widely by plan and region.
Part D benefit structure has evolved substantially. Historically, Part D featured a "donut hole" coverage gap where beneficiaries paid substantial cost-sharing for drugs purchased in the middle cost band. The Affordable Care Act and subsequent legislation gradually closed the donut hole. The Inflation Reduction Act of 2022 made the most significant structural changes since Part D's creation: capped annual out-of-pocket spending at $2,000 for 2025 and subsequent years; redesigned the standard benefit into three simplified phases (deductible, initial coverage, catastrophic); and enabled CMS to negotiate prices on a growing list of high-cost drugs beginning 2026.
For 2025, the standard Part D benefit structure: $590 annual deductible; 25% beneficiary coinsurance in initial coverage phase; $2,000 annual out-of-pocket cap at which point plan covers 100% with no further beneficiary cost-sharing for the rest of the year. Plans can offer "enhanced" benefit designs with lower deductible, additional coverage, or reduced cost-sharing in exchange for higher premium.
For RCM, Part D directly affects physician billing only through the 340B drug pricing program for covered entity hospitals. Drug dispensing occurs at pharmacies, not physician offices; pharmacy billing uses the NCPDP Telecommunication Standard, not the HIPAA 837. However, physician-prescribing workflow affects Part D: formulary restrictions, prior authorization, step therapy, quantity limits. Providers spend substantial time navigating Part D plan-specific prescribing rules; e-prescribing platforms with formulary-aware prescribing save time but never fully eliminate the administrative burden.
Low-Income Subsidy (LIS), also called "Extra Help," is a federal program that subsidizes Part D premiums and cost-sharing for low-income beneficiaries. LIS-qualified beneficiaries pay reduced or zero premiums and face reduced cost-sharing; the federal government subsidizes the difference. Approximately 15 million beneficiaries receive LIS; the 2023–2025 legislation expanded LIS eligibility.
Part D Star Ratings measure plan performance on adherence, customer service, and other dimensions. Plans with strong Star Ratings receive Quality Bonus Payments and have marketing advantages during Annual Enrollment Period. Medication adherence measures (for diabetes, hypertension, statins) have high weights and drive significant plan investment in adherence-boosting interventions — medication synchronization, pharmacist outreach, automatic refill programs, and member education.
The IRA's CMS drug-price negotiation program is reshaping Part D economics. The first ten drugs negotiated (effective 2026) include blockbuster products. CMS publishes "Maximum Fair Prices" that Medicare and negotiating manufacturers must honor; plan formularies will reflect these prices. The negotiated drug list expands annually through the mid-2020s and is expected to produce meaningful federal savings while affecting manufacturer economics and plan benefit design.
Industry benchmark
CMS Part D annual guidance via Medicare Part D Manual. CMS IRA Drug Price Negotiation Program. KFF Medicare Part D and IRA analysis.
Worked example
A 74-year-old in a Part D PDP fills 7 prescriptions monthly for chronic conditions. Q1: pays $590 deductible rapidly (7 Rx × average $78 = $546 plus a single specialty Rx at $850). Q2–Q3: 25% coinsurance on each Rx. Reaches $2,000 OOP cap by Q3. Q4: $0 cost-sharing on all Rx through year-end — including a specialty oncology Rx costing $4,800/month. Year-total beneficiary OOP: $2,000 (capped). Historical (pre-IRA) same pattern would have exposed beneficiary to $12K+ annual OOP.
Frequently asked questions — Medicare Part D
How do I enroll in Medicare Part D?
During the Initial Enrollment Period around age-65 eligibility, or during the Annual Enrollment Period (October 15 – December 7) each year. Beneficiaries enroll in a PDP (Prescription Drug Plan) to go with Original Medicare or in an MA-PD (Medicare Advantage with prescription drug coverage) that bundles Part D with Part C.
What's the Part D donut hole?
Historically, a coverage gap where beneficiaries paid a higher share of drug costs in a middle cost band. Progressively closed by ACA and subsequent legislation; fully eliminated in the simplified IRA benefit structure effective 2025, replaced with a hard $2,000 out-of-pocket cap and three simplified benefit phases.
How does Low-Income Subsidy work?
Beneficiaries with income below 150% FPL and limited assets can qualify for LIS (Extra Help), which pays Part D premium and reduces cost-sharing. Full LIS: zero premium, nominal copays ($4–$12). Partial LIS: reduced premium, reduced cost-sharing. Approximately 15M beneficiaries receive LIS; eligibility expansions took effect 2024.
Can providers bill Medicare directly for Part D drugs?
Generally no — Part D drugs are dispensed at pharmacies and billed under NCPDP pharmacy billing, not HIPAA 837. Provider-administered drugs (injectables, chemotherapy in office) are typically covered under Part B, not Part D. 340B-eligible hospital providers have additional pricing considerations but the billing form remains Part B for provider-administered drugs.
Disclaimer
This glossary entry is operational reference for revenue-cycle and medical-billing professionals. It is not legal, clinical, or contractual advice. Industry benchmarks cite named public sources where available; always verify against the current guidance from the authority body before relying on a number in a contract, policy, or compliance filing.